Owlstone Medical Secures 1.7m for Breath Test Innovation

Deal News | Mar 25, 2025 | Business Cloud

Cambridge-based Owlstone Medical has announced a significant funding round, securing £1.7 million from the Cystic Fibrosis Foundation to develop an innovative breath test for the detection of Pseudomonas aeruginosa (PA) in cystic fibrosis patients. PA is a notable pathogen threatening the health of individuals with this genetic disorder, affecting 25% of patients and representing a critical target for early detection and treatment. Owlstone Medical, a leader in breath biopsy technology, plans to utilize its proprietary Breath Biopsy platform for the task. The study intends not only to improve clinical outcomes but also to contribute data to the comprehensive Breath VOC Atlas for further research. CEO Billy Boyle emphasized the company's readiness to make an impact through its experience in breath-based detection projects and strategic partnerships.

Sectors

MedTech
Biotechnology

Geography

United Kingdom – Owlstone Medical is based in Cambridge, UK, making this a relevant geographical area for the article.

Industry

MedTech – The article discusses Owlstone Medical's development of a breath test for medical purposes, placing it within the MedTech industry.
Biotechnology – The development of a diagnostic test for disease detection categorizes this as a biotechnology endeavor, involving biological data analysis.

Financials

1.7m – The amount of funding received by Owlstone Medical from the Cystic Fibrosis Foundation.

Participants

Name	Role	Type	Description
Owlstone Medical	Recipient	Company	A Cambridge-based MedTech company specializing in breath biopsy technology for early disease detection.
Cystic Fibrosis Foundation	Funder	Charity	A foundation dedicated to supporting research and treatment initiatives for cystic fibrosis, providing funding to Owlstone Medical.
Billy Boyle	Spokesperson	Person	Co-founder and CEO of Owlstone Medical, providing comments on the company's strategic position and innovations.